Α-氯-2-氯-6-氟苯甲醛肟 | 51088-25-6

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: Α-氯-2-氯-6-氟苯甲醛肟
• 英文名称: (Z)-2-chloro-6-fluoro-N-hydroxybenzimidoyl chloride
• 英文别名: Benzenecarboximidoyl chloride, 2-chloro-6-fluoro-N-hydroxy-；(1Z)-2-chloro-6-fluoro-N-hydroxybenzenecarboximidoyl chloride
• CAS: 51088-25-6
• 化学式: C₇H₄Cl₂FNO
• 分子量: 208.019
• InChiKey: XQUJVGVNTYDLIG-XFFZJAGNSA-N

物化性质

• 沸点：
  309.1±52.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Α-氯-2-氯-6-氟苯甲醛肟 在 sodium ethanolate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 14.0h， 生成 (E)-methyl 3-(2-chloro-6-fluorophenyl)-5-(2-(dimethylamino)vinyl)isoxazole-4-carboxylate
  参考文献：
  名称：

  [EN] METHODS FOR TREATING CANCER
  [FR] MÉTHODES DE TRAITEMENT DU CANCER

  摘要：

  The present invention provides methods comprising one or compounds according to Formula (I) alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g. prostate cancer, such as castration-resistant prostate cancer (CRPC) and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma and glioma.

  公开号：

  WO2023281097A1

文献信息

• [EN] 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-17 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION<br/>[FR] DÉRIVÉS DE 1-(4-(ISOXAZOL-5-YL)-1 H-PYRAZOL-1-YL)-2-MÉTHYLPROPAN-2-OL ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS D'IL-17 ET D'IFN-GAMMA POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET D'UNE INFLAMMATION CHRONIQUE
  申请人：IMMUNIC AG

  公开号：WO2019048541A1

  公开（公告）日：2019-03-14

  The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure (formula (II)), wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trilluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation.

  本发明涉及具有通用公式（I）的化合物，以及其中Ar、Z和Y如本文所述的药用可接受盐和溶剂化物，其中R1是具有结构（公式（II））的组，其中n为0或1；R2是H，氘或甲基；R3是甲基，三氟甲基，乙基，或者与R2共同形成一个环丙基组，或者R3形成一个甲基桥接到标记为*的碳原子上，这些化合物适合用于治疗自身免疫性疾病和慢性炎症。
• IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION
  申请人：LEBAN Johann

  公开号：US20120196861A1

  公开（公告）日：2012-08-02

  The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

  本发明涉及通式（I）的化合物，以及其药用可接受的盐或溶剂，作为抗炎和免疫调节剂。
• Compounds and methods for inhibiting MRP1
  申请人：——

  公开号：US20040077675A1

  公开（公告）日：2004-04-22

  The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1. 1

  本发明涉及一种式（I）的化合物，该化合物对于抑制由MRP1.1部分或全部赋予的耐药性肿瘤是有用的。
• Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
  申请人：FORUM PHARMACEUTICALS, INC.

  公开号：US10370370B2

  公开（公告）日：2019-08-06

  The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of Alpha7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及适用于作为 Alpha7-nAChR 激动剂或部分激动剂的新型氨基苯并异噁唑化合物及其药物组合物、制备这些化合物和组合物的方法，以及将这些化合物和组合物用于维持、治疗和/或改善认知功能的方法。特别是，将化合物或组合物施用给有需要的患者的方法，例如，有认知缺陷和/或希望提高认知功能的患者，这些患者可从中获益。
• Hormone receptor modulators for treating metabolic conditions and disorders
  申请人：ARDELYX, INC.

  公开号：US10793568B2

  公开（公告）日：2020-10-06

  The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

  本发明涉及用于治疗自身免疫性疾病、肝脏疾病、肠道疾病、肾脏疾病、癌症和其他 FXR 起作用的疾病的 FXR 激活剂，其具有式 (I)：(I)，其中 L1、A、X1、X2、R1、R2 和 R3 如本文所述。